stonedinvestor
Registered: Mar 2006
Posts: 3398 |
01-25-13 01:54 PM
[QUOTE][i]Quote fromstonedinvestor
WHERE THE F AM I? WHY HAVE THE NY GIANTS NOT MADE THE PLAYOFFS? This thread it popped up in my mail... I had forgotten all about my friends... I feel bad. Hi Jack!
I have sold my position in Exact Sciences a long time ago. Thanks for bringing the name back to my attention.
Stool-based DNA (sDNA) technology and colorectal cancer screening never gets old. The results of the DeeP-C trial currently underway are expected to form the basis for submitting the non-invasive test for Pre-Market Approval with the FDA.
The DeeP-C study is a follow up to the company's recently presented results of a 1,003-patient case-control study that used the same technology as the DeeP-C trial. Among the study population, there were 93 cases of colorectal cancer, 114 cases of advanced pre-cancers and 796 controls. The Exact Sciences test detected 98% of colorectal cancers and 83% of pre-cancers with high-grade dysplasia, the majority of which progress to cancer.
The test demonstrated 57% sensitivity in the detection of advanced pre-cancers equal to or larger than 1 centimeter. The test's sensitivity increased with the size of the pre-cancers, rising to 83% for pre-cancers larger than 3 centimeters.
The company has three upcoming milestones in the approval process that should serve as catalysts for the stock.
In February, the company plans to submit the 2nd FDA module.
In March, Exact Sciences expects to announce topline results in the DeeP-C study.
In the April-May time period, the company plans to submit an application with the Centers for Medicare & Medicaid Services as well as submit the final FDA module containing clinical data.
Projections of Exact Sciences' annual revenue from this product top $500 million. The company now has virtually no revenues.
-Global opportunity is greater than $3 billion, with $1.2 billion of that being in the US.
-Roughly one-third of colorectal cancer-related deaths could be avoided with regular screening. Of those diagnosed, nearly half are expected to die within five years because most cases are detected when cancer has progressed and is less treatable. For those whose cancer is detected at an earlier stage, the five-year survival rate can be greater than 90%.
Personally Jack I don't like what I've heard about these regular tests for colon cancer. It sounds messy and impersonal and I won't do it. This product from EXACT SCIENCES could be a life saver for me.
Anyway I hope you are doing well and thanks for getting in touch. ~stoney
|
